Screener
Bausch Health Companies BHC Diversified — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch Health Companies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 6:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885590-26-000053
| (in millions) | Three Months Ended March 31, / Salix / 2026 | Three Months Ended March 31, / Salix / 2025 | Three Months Ended March 31, / International / 2026 | Three Months Ended March 31, / International / 2025 | Three Months Ended March 31, / Solta Medical / 2026 | Three Months Ended March 31, / Solta Medical / 2025 | Three Months Ended March 31, / Diversified / 2026 | Three Months Ended March 31, / Diversified / 2025 | Three Months Ended March 31, / Bausch + Lomb / 2026 | Three Months Ended March 31, / Bausch + Lomb / 2025 | Three Months Ended March 31, / Total / 2026 | Total / 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of goods sold (a) | 47 | 43 | 112 | 102 | 53 | 27 | 27 | 30 | 482 | 481 | ||
| Cost of other revenues | — | — | 16 | 17 | — | — | — | — | 1 | 1 | ||
| Selling, general and administrative | 105 | 111 | 63 | 52 | 35 | 28 | 43 | 45 | 439 | 447 | ||
| Research and development | 19 | 17 | 6 | 6 | 8 | 5 | 3 | 3 | 45 | 28 | ||
| Segment profit | $468 | $371 | $88 | $85 | $75 | $53 | $112 | $127 | $277 | $180 | $1,020 | $816 |
| Corporate | (258) | (268) | ||||||||||
| Amortization of intangible assets | (241) | (256) | ||||||||||
| Goodwill impairments | (1,426) | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch Health Companies's diversified — R&D?
- Bausch Health Companies (BHC) reported diversified — R&D of $3M in Q1 2026.
- How has Bausch Health Companies's diversified — R&D changed year-over-year?
- Bausch Health Companies's diversified — R&D decreased by 0.0% year-over-year, from $3M to $3M.
- What is the long-term trend for Bausch Health Companies's diversified — R&D?
- Over 3 years (2022 to 2025), Bausch Health Companies's diversified — R&D has grown at a -17.6% compound annual growth rate (CAGR), from $25M to $14M.
- What does diversified — R&D mean?
- Captures the costs incurred for research and development activities specifically dedicated to the Diversified segment's product pipeline. This investment is critical for long-term innovation and maintaining the competitive edge of the segment's product portfolio. It reflects the company's commitment to future growth through scientific advancement.
Ask your AI about Bausch Health Companies's diversified — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude